Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitcoin Outlook Holds Firm Above Key Support

Bitcoin Outlook Holds Firm Above Key Support

CryptonewslandCryptonewsland2026/07/17 16:39
By:Cryptonewsland
  • Bitcoin Outlook remains constructive as BTC holds above $64,000 despite recent profit-taking after testing the $65,700 resistance level.
  • Exchange inflows are also thin, indicating that holders are not undertaking any large-scale selling; the volume is lower than in previous years.
  • Bitcoin Outlook depends on defending higher lows before another challenge of the $65,700 resistance zone develops.

Bitcoin Outlook is bullish after the recent profit taking yet traders are keeping an eye on key support levels as they await confirmation of Bitcoin’s next reversal as the U.S. inflation data came in lighter than expected.

Bitcoin Holds Key Support Following Inflation-Driven Rally

Bitcoin failed to pick up on the $65,700 resistance zone, marking a pullback, said CryptoSavingExpert. The analyst characterized the move as a “normal” profit-taking move. The broader market structure remained constructive despite the temporary decline.

Bitcoin Outlook Holds Firm Above Key Support image 0 Source:

The 4-hour chart allowed the traders to see the resistance of the important $64,000 level by the buyers. This level previously acted as resistance during the recent advance. Its successful retest strengthened the current recovery structure.

Price action remained orderly throughout the latest pullback. Large bearish breakdown candles never appeared during the correction. Selling pressure also failed to invalidate the recent sequence of higher lows.

The chart identified $63,000 as immediate secondary support beneath current prices. Stronger structural support remained visible around $61,000. Meanwhile, the $59,000-$59,500 zone continued representing the major long-term demand area.

Exchange Inflows Point Toward Measured Market Positioning

CryptoQuant data presented another perspective supporting the current market environment. Bitcoin exchange inflows remained relatively contained during recent consolidation. Large-scale selling activity therefore appeared limited.

Bitcoin Outlook Holds Firm Above Key Support image 1 Source:

Historical data showed major inflow spikes exceeding 100,000 BTC during previous volatile periods. Those movements accompanied rapid price swings throughout earlier market cycles. Even then, Bitcoin continued advancing after several elevated inflow events.

Recent exchange deposits measured roughly 22,100 BTC, remaining well below historical extremes. That reading suggested reduced urgency among larger holders. Market participants appeared comfortable maintaining existing positions despite recent weakness.

Moderate inflows also indicated balanced market participation instead of widespread distribution. Heavy exchange transfers typically accompany stronger liquidation activity. Current figures instead reflected patience while traders awaited stronger directional confirmation.

Bitcoin Outlook Depends on Reclaiming Resistance

Bitcoin as of the time of writing is  trading at $64,041 after declining 2.1% during twenty-four hours. Even so, intraday movements remained relatively controlled. Buyers repeatedly responded whenever prices approached lower trading levels.

The session briefly lifted Bitcoin above $65,300 before renewed selling emerged. Profit-taking quickly limited further upside progress. Consequently, prices returned beneath the nearby resistance region.

Trading volume reached approximately $30.26 billion during the reporting period. Market capitalization remained close to $1.28 trillion despite recent weakness. Circulating supply also remained near the protocol’s maximum issuance schedule.

The Bitcoin Outlook now depends on sustained defense above $64,000 support. A successful recovery could encourage another attempt toward $65,700 resistance. Until then, consolidation continues within an intact bullish technical framework.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26